Shared on08 Aug 25Fair value Increased 12%
Elanco Animal Health’s consensus price target has been raised to $17.45, driven by improved business stability, accelerating growth from an enhanced innovation pipeline, and increased traction of its product CQ. Analyst Commentary Improved core business stability driven by better execution, providing a firmer foundation for future product innovation.
Shared on29 Jul 25Fair value Increased 13%
Analysts have raised Elanco Animal Health's price target from $13.80 to $15.55, citing improved core business execution, growing traction of innovation products, and increased confidence in management and the product pipeline. Analyst Commentary Bullish analysts cite stabilization in Elanco's core business due to improved execution, creating a stronger base for future innovation-driven growth.
Shared on01 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on24 Apr 25Fair value Decreased 5.28%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 2.61%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 2.79%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Increased 5.81%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.